SCHEMBL1637799

SCHEMBL1637799

OC(c1ccccc1)c1cccc(Br)c1OCc1ccccc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
THRB P10828 2/20 0.43
THRA P10827 1/20 0.43
KMT2A Q03164 5/20 0.42
MEN1 O00255 3/20 0.42
TDP1 Q9NUW8 1/20 0.42
MAPT P10636 4/20 0.40
GAA P10253 4/20 0.40
HPGD P15428 3/20 0.40
MAOB P27338 1/20 0.40
SMN1; SMN2 Q16637 4/20 0.38
GLRA1 P23415 1/20 0.38
LMNA P02545 2/20 0.38
HTT P42858 2/20 0.38
ALOX15 P16050 1/20 0.38
TSHR P16473 1/20 0.38
MAPK1 P28482 1/20 0.38
KDM4E B2RXH2 1/20 0.38
ALDH1A1 P00352 1/20 0.38
BLM P54132 1/20 0.38
DRD2 P14416 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1639177 0.81 LMNA (0.42) KMT2AMEN1MAPTGAAHPGD
SCHEMBL6761856 0.81 SMN1; SMN2 (0.48) THRBTHRAKMT2AMEN1TDP1
SCHEMBL28005951 0.80 GLRA1 (0.50) THRBTHRAKMT2AMEN1TDP1
SCHEMBL12765218 0.80 MEN1 (0.40) THRBTHRAKMT2AMEN1MAPT
SCHEMBL1642760 0.79 FEN1 (0.43) KMT2AMEN1TDP1MAPTHPGD
SCHEMBL1154801 0.79 THRB (0.56) THRBTHRAKMT2AMEN1TDP1
SCHEMBL28006266 0.77 KMT2A (0.42) THRBTHRAKMT2AMEN1TDP1
SCHEMBL477534 0.76 DRD2 (0.55) TDP1MAPTLMNAMAPK1KDM4E
SCHEMBL29895092 0.75 THRB (0.43) THRBTHRAKMT2AMEN1TDP1
SCHEMBL4962230 0.74 HTR1A (0.50) THRBTHRAKMT2AMEN1TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8541521-B2 Catalyst compounds and use thereof EXXONMOBIL CHEMICAL PATENTS INC. (US) 2013-09-24 US disclosed
US-8541521-B2 Catalyst compounds and use thereof EXXONMOBIL CHEMICAL PATENTS INC. (US) 2013-09-24 US disclosed
EP-2493933-A2 CATALYST COMPOUNDS AND USE THEREOF ExxonMobil Chemical Patents Inc. (US) 2012-09-05 EP disclosed
WO-2011056424-A2 CATALYST COMPOUNDS AND USE THEREOF EXXONMOBIL CHEMICAL PATENTS INC. (US) 2011-05-12 WO disclosed
US-20110098427-A1 Catalyst Compounds And Use Thereof EXXONMOBIL CHEMICAL PATENTS INC. 2011-04-28 US disclosed
US-20110098427-A1 Catalyst Compounds And Use Thereof EXXONMOBIL CHEMICAL PATENTS INC. 2011-04-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110098427-A1 Catalyst Compounds And Use Thereof THEM6, OPRM1, NOTUM THRB 4402/4885THRA 4260/4885KMT2A 3528/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.